| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao Chen, Xi-Heng Sun, Yue Xiao, Dan Zhang, Xiao-Yan Lu, Cheng-Lei Fu, Chun Bi and Xia Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xia Wang, Chief Physician, Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 9 Kunpeng North Road, Xuzhou 221004, Jiangsu Province, China. wangxia_66@163.com |
| Key Words |
Intrahepatic cholangiocarcinoma; Transarterial chemoembolization; Programmed death 1/programmed cell death ligand 1 inhibitors; Tyrosine kinase inhibitors; Efficacy |
| Core Tip |
This study retrospectively evaluated the efficacy and safety of transarterial chemoembolization combined with chemotherapy, tyrosine kinase inhibitors, and programmed death 1/programmed cell death ligand 1 inhibitors in patients with intrahepatic cholangiocarcinoma. In conclusion, the combination of transarterial chemoembolization with chemotherapy, tyrosine kinase inhibitors, and programmed death 1/programmed cell death ligand 1 inhibitors demonstrates good efficacy and a favorable safety profile, offering potential benefits for patients with intrahepatic cholangiocarcinoma. |
| Publish Date |
2025-09-15 08:38 |
| Citation |
<p>Chen X, Sun XH, Xiao Y, Zhang D, Lu XY, Fu CL, Bi C, Wang X. Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(9): 103816</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/103816.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.103816 |
